SCHEMBL1555065

SCHEMBL1555065

Cc1ccc(CC(=O)c2ccccc2)cc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.54
MEN1 O00255 4/20 0.54
NPC1 O15118 4/20 0.54
RAB9A P51151 4/20 0.54
CES1 P23141 2/20 0.53
CES2 O00748 1/20 0.53
L3MBTL1 Q9Y468 4/20 0.51
GAA P10253 2/20 0.51
LMNA P02545 2/20 0.51
PSMB8 P28062 2/20 0.49
PSMB5 P28074 2/20 0.49
PLAU P00749 1/20 0.47
MAPT P10636 3/20 0.47
SRD5A2 P31213 3/20 0.46
MGAM O43451 1/20 0.46
AMY1A P0DUB6 1/20 0.46
SI P14410 1/20 0.46
MGAM2 Q2M2H8 1/20 0.46
KDM4E B2RXH2 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18316540 0.85 PLAU (0.47) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL18316819 0.85 NPC1 (0.47) KMT2AMEN1NPC1RAB9ACES1
SCHEMBL30486043 0.85 MAPT (0.51) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL28013348 0.83 NPC1 (0.51) KMT2AMEN1NPC1RAB9ACES1
SCHEMBL12442481 0.83 RAB9A (0.68) KMT2AMEN1NPC1RAB9AL3MBTL1
SCHEMBL7040136 0.82 CES2 (0.58) NPC1RAB9ACES1CES2L3MBTL1
SCHEMBL12820020 0.81 USP2 (0.59) KMT2AMEN1L3MBTL1GAALMNA
SCHEMBL28042412 0.81 PLAU (0.46) KMT2AMEN1NPC1RAB9ACES1
SCHEMBL28042191 0.81 MAPT (0.46) KMT2AMEN1NPC1RAB9ACES1
SCHEMBL7199268 0.80 MAPT (0.67) KMT2AMEN1NPC1RAB9ACES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916711-B2 Imidazothiazole-chalcone derivatives as potential anticancer agents and process for the preparation thereof COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2014-12-23 US disclosed
EP-2488533-B1 IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL SCIENT IND RES (IN) 2014-07-23 EP disclosed
US-20120271054-A1 IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-10-25 US disclosed
EP-2488533-A1 IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF Council of Scientific & Industrial Research (IN) 2012-08-22 EP disclosed
WO-2011045646-A1 IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120271054-A1 IMIDAZOTHIAZOLE-CHALCONE DERIVATIVES AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF EIF4A1, CYP2C18, UGT2B17 KMT2A 1313/4885MEN1 2545/4885NPC1 1594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.